Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure (AI-PRESENCE HF)

9 novembre 2026 mis à jour par: In-Cheol Kim, Keimyung University Dongsan Medical Center

Effects of Primary Physician Presence in SGLT2 Inhibitor-Focused Heart Failure Educational Videos During Outpatient Waiting Time on Patient Satisfaction and Educational Effectiveness : A Randomized 2x2 Factorial Study

The purpose of this study is to evaluate the effect of the primary attending physician's presence in educational videos on patient satisfaction and educational effectiveness.

Aperçu de l'étude

Description détaillée

The videos, generated using AI technology, focus on SGLT2 inhibitors and are provided to heart failure patients during their outpatient clinic waiting time.

In this single-center, randomized, 2x2 factorial study, participants will be assigned to one of four groups based on two factors: the specific doctor featured in the video (Doctor A vs. Doctor B) and the physician's role presentation (presented as the patient's actual attending physician vs. a non-attending general cardiologist).

All participants will watch the assigned educational video during their waiting time and then proceed with their scheduled outpatient consultation. After the consultation, participants will complete a single survey. The survey will assess overall patient satisfaction, the perceived usefulness of the education, and the objective understanding of the video's key messages regarding heart failure management and SGLT2 inhibitors.

Type d'étude

Interventionnel

Inscription (Estimé)

150

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Incheol Kim, MD
  • Numéro de téléphone: +82-53-258-4625
  • E-mail: kimic@dsmc.or.kr

Lieux d'étude

      • Daegu, Corée du Sud, 42601
        • Recrutement
        • Keimyung University Dongsan Medical Center
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

19 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients diagnosed with heart failure or those visiting the cardiology outpatient clinic with suspected heart failure symptoms (e.g., dyspnea, edema).
  • Patients currently taking or scheduled to be prescribed SGLT2 inhibitors for the treatment of heart failure.
  • Patients who are able to watch the educational video during the outpatient waiting time and complete the survey after the consultation.
  • Patients who fully understand the purpose and procedures of this study and voluntarily provide written informed consent.

Exclusion Criteria:

  • Patients who do not understand the contents of this study or do not consent to the study due to cognitive decline, etc.
  • Patients with expected acute exacerbation of heart failure or a life expectancy of 1 year or less.
  • Patients who have difficulty watching the video due to visual or hearing impairments.
  • Patients scheduled for heart failure-related surgery or procedures.
  • Patients who are currently participating in, or have participated in within the past 6 months, another intervention study related to heart failure education.
  • Other patients deemed inappropriate for study participation by the investigator.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation factorielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Doctor A - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Autres noms:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparateur actif: Doctor A - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Autres noms:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Expérimental: Doctor B - Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as their primary physician.

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Autres noms:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video
Comparateur actif: Doctor B - Non-Attending Physician Video

Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as a general cardiologist (non-attending).

Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

Autres noms:
  • Outpatient Waiting Time Education
  • AI-Synthesized Physician Video

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Patient Satisfaction Score
Délai: Immediately after the outpatient clinic visit (Day 0)

Patient satisfaction regarding the positive impact and helpfulness of the educational video on the subsequent outpatient consultation process. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates a higher level of patient satisfaction.

Immediately after the outpatient clinic visit (Day 0)
Educational Usefulness Score
Délai: Immediately after the outpatient clinic visit (Day 0)

The perceived usefulness of the educational video in understanding heart failure treatment methods, specifically the role, effects, and precautions of SGLT2 inhibitors. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates greater perceived educational usefulness and understanding.

Immediately after the outpatient clinic visit (Day 0)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Educational Content Delivery Effectiveness Score
Délai: Immediately after the outpatient clinic visit (Day 0)

An objective assessment of the patient's understanding of the video's key messages, such as heart failure management and SGLT2 inhibitor information. It is evaluated based on the number of correct answers to 4 multiple-choice questions derived directly from the video's core content. The total score ranges from 0 to 4, where 1 point is awarded for each correct answer. A higher score indicates a better understanding and a higher level of correct knowledge acquisition.

Immediately after the outpatient clinic visit (Day 0)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 août 2026

Achèvement primaire (Estimé)

31 juillet 2027

Achèvement de l'étude (Estimé)

31 juillet 2027

Dates d'inscription aux études

Première soumission

9 novembre 2026

Première soumission répondant aux critères de contrôle qualité

9 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2026-06-008

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner